Furthermore , among patients in the top quartile of FGF-@ levels , trandolapril significantly reduced cardiovascular death or incident heart failure ( hazard ratio : @ ; @ % confidence interval : @ to @ ) , whereas there was no clinical benefit in the remaining patients ( hazard ratio : @ ; @ % confidence interval : @ to @ ; p interaction = @ ) .